Why I think shares in this AIM-listed pharmaceuticals data company could be set to rise

Diaceutics specialises in big data applied to precision medicine, a market that could be set to change the world of medicine. I think Diaceutics shares could be massive winners.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Not so long ago, the benefits of big data were poorly understood. Similarly, precision medicine was so niche that very few pharmaceutical companies understood the potential.

These days, the precision medicine market is worth around $50bn a year, but is expected to almost double in size by 2024, according to research from Absolute Market Insights. There is a good reason for this: precision medicine is likely to save lives.

One company that could be set to benefit from this revolution in precision medicine is AIM-listed Diaceutics (LSE:DXRX).  

The Diaceutics CEO Peter Keeling tells a story about how he gave a talk around 13 years ago at a conference on the importance of using data in diagnostic testing. As the talk continued the room slowly emptied, leaving just a handful of people.

Most visionaries can probably tell a similar tale — it’s tough getting people to listen to ideas that are at the pioneering end of business and technology. Fortunately for Keeling, two of the people who sat through his talk to the end, and spoke to him afterwards, were from GSK and AstraZeneca. As this tale illustrates, Diaceutics was there right at the inception of the precision medicine business.

The revolution in data and the pharmaceutical space can probably be dated back to the beginning of the century, when the human genome was first sequenced. The way the cost of genome sequencing has fallen, from $2.7bn in 2003 to less than $1,000 today, is perhaps the most remarkable achievement of the century so far.

The combination of genome sequencing technology with ever faster and more powerful computers, AI, and data generated from wearable devices could transform medicine. It is truly exciting stuff. 

A lake of anonymised data

As for Diaceutics, the company is in the business of providing its expertise to the pharmaceutical industry. It owns a proprietary database which it recently expanded with a £1m acquisition of a data lake — 16 million additional patient records a year. The data is anonymised, meaning there are minimal privacy issues.

The company joined the stock market last year when it raised £17m. Since IPO, shares have increased 20%. Recently, Diaceutics revealed a trading update for the year to 31 December. Earnings before interest, tax, depreciation and amortisation (EBIDTA) for the year is projected to be around £13.4m, roughly 30% up on last year. That’s £2.1m ahead of market expectations.

The company has no debt, £11.7m in net cash, and has built up an impressive team of experts.

It’s the company’s expertise in data from precision medicine that excites me, however. It recently released a report claiming that half of eligible cancer patients are not benefiting from potential life-saving precision medicines because they are not receiving appropriate tests. That finding alone shows how enormously important precision medicine will be in the pharmaceutical industry as this decade unfolds.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Michael Baxter has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »